Swedish drugmaker Orexo has finished early lab testing on its own tablet version of semaglutide, the drug behind Ozempic and Wegovy.
Recap by typeshit. Full story at TradingView.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
A market update credits new generics and steady prices for the rise in sales value, with Eli Lilly's tirzepatide featured in the numbers.
Medscape weighs GLP-1 medications against finerenone to see which does more to protect the kidneys.
Loading…